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INTRODUCTION
The overall incidence of ovarian tumors in pregnancy is
2.4-5.7% (1). Of these tumors, approximately 5% are malig-
nant (2, 3). Currently, an ultrasound is routinely used early
in pregnancy, and this has led to an early diagnosis and man-
agement of asymptomatic ovarian tumors. 
In contrast to previous guidelines for managing gyneco-
logical malignancies in pregnancy, today, most women with
ovarian cancer complicating pregnancy hope to maintain the
pregnancy and preserve fertility, which has been encouraged
by late maternity and a low birthrate. 
In the absence of large prospective randomized trials and
cohort studies, it is difficult to know how to manage patients
best and make standard guidelines for management of these
tumors during pregnancy. To establish standard a guideline
for management of ovarian cancer complicating pregnancy,
it is necessary to identify surgical strategies with or without
adjuvant intrapartum chemotherapy that results in safe onco-
logic and fetal outcomes. This study was undertaken to help
establish a guideline for management of ovarian malignancy
complicating pregnancy.
MATERIALS AND METHODS
We retrospectively analyzed the medical records of patients
(n=27) with ovarian cancer complicating pregnancy who were
treated at Cheil General Hospital and Women’s Healthcare
Center between January 1996 and November 2006. In these
patients, the ovarian cancer was detected during gestation. 
Twenty-five of these patients were diagnosed in our insti-
tute, and two were transferred from other hospitals. Conser-
vative surgical management was defined as cystectomy, or
unilateral salpingo-oophorectomy (USO), or USO with omen-
tectomy and multiple biopsies. Specialized pathologists at our
institution reported findings of intra-operative frozen biop-
sies and post-operatively confirmed pathology specimens for
all 27 patients. The 1988 FIGO Staging System was retro-
spectively used for each case after reviewing the operative
reports and pathologic findings. Patients were followed up
with clinical, serum tumor marker and radiologic assessments.
Follow-up information was recorded up to the date of last
contact or death. 
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Ovarian Cancer during Pregnancy: Clinical and Pregnancy Outcome
The aim of this study is to evaluate the clinical feature and pregnancy outcome in
patients with ovarian cancer diagnosed during pregnancy. We retrospectively ana-
lyzed the medical records of 27 patients diagnosed with ovarian cancer during preg-
nancy at Cheil General Hospital & Women’s Healthcare Center from January 1996
to December 2006. Mean age of the patients was 29.1 yr (range 23-40), and a mean
follow-up period was 57 months (range 7-112 months). Of 27 patients, 15 (55.5%)
had borderline malignancies, 7 (25.9%) had epithelial malignancies and 5 (18.6%)
had germ cell tumors. A total of 26 patients received a conservative surgery pre-
serving pregnancy. The mean time for surgical intervention during pregnancy was
20 weeks of gestational age. Of the 27 patients, 26 had full term delivery of a healthy
baby without any congenital malformation. Only one patient with epithelial ovarian
cancer had a relapse at 19 months after the first conservative operation with adju-
vant chemotherapy. There were few data for managing patients with ovarian can-
cer diagnosed during pregnancy. This study results could help establish a guide-
line for management of ovarian malignancy complicating pregnancy.
Key Words : Ovarian Neoplasms; Pregnancy; Conservative Surgery
Received : 24 December 2008
Accepted : 24 April 2009
ⓒ 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.Ovarian Cancer during Pregnancy: Clinical and Pregnancy Outcome 231
RESULTS
Mean age of the patients was 29.1 yr (range 23-40). Of
27 patients with ovarian tumor complicating pregnancy, 25
were diagnosed during pregnancy and the others were inci-
dentally diagnosed at cesarean section. Mean time of diagno-
sis of ovarian tumor was 12.5 weeks of gestational age (GA)
(range 5.0-41.0 weeks of GA). In the patients diagnosed dur-
ing pregnancy, 6 had the presenting symptoms such as ab-
normally distended abdomen due to huge ovarian tumor.
Most patients without symptoms (n=21) were diagnosed
incidentally at early GA by a routine ultrasound examina-
tion (Table 1). 
Histopathologic characteristics included ovarian border-
line malignancy (n=15), epithelial ovarian cancers (EOC)
(n=7) and malignant germ cell tumors (GCT) (n=5). The
clinical and pathologic profiles of the 27 patients are shown
in Table 2. The mean size of the ovarian tumors measured
by ultrasound sonogram was 11.4 cm (range, 4-22 cm) and
three of 27 patients had an ovarian tumor less than 6 cm in
diameter.
All patients underwent surgical management for the ini-
tial treatment. The initial operation included a conservative
operation (n=26) and a cytoreductive operation with hysterec-
tomy (n=1). The conservative surgical management includ-
ed cystectomy (n=10), USO (n=13) and USO with omen-
tectomy and multiple biopsy (n=3). Patients with ovarian
borderline malignancies underwent cystectomy (n=7), USO
(n=6) or USO with omentectomy and multiple biopsy (n=2).
No recurrence occurred in any patient with the borderline
malignancy. The patients with germ cell tumor underwent
cystectomy (n=2), USO (n=2) or USO with omentectomy
and multiple biopsy (n=1), with no recurrence in any patient
with malignant germ cell tumor. In the patients with EOC,
the surgical approaches were cystectomy (n=1), USO (n=5)
or cytoreductive operation with hysterectomy (n=1). In this
group, one patient recurred (Table 3).
Of the 22 patients who underwent surgical interventions
during pregnancy, there were no definite feto-maternal com-
plications after surgical management. Of these 22 patients,
nineteen (86.4%) received surgical intervention during sec-
ond trimester and three (13.6%) during the first trimester.
A total of 8 patients received adjuvant chemotherapy; 3
patients received chemotherapy with fetus in utero, and 5
patients received chemotherapy just after delivery. One pati-
*symptomatic, the presenting symptoms as abnormally distended ab-
domen due to huge ovarian tumor; 
� all patients had succeeded full term
deliveries.
No. of patients %
Age 29.1 yr (range 23-40)
Time at diagnosis
Trimester 1 20 70.1
Trimester 2 4 14.8
Trimester 3 1 3.7
Puerperium 2 7.4
Presenting symptoms
Asymptomatic 21 77.8
Symptomatic* 6 22.2
Time at surgical intervention
Trimester 1 3 11.1
Trimester 2 19 70.1
Trimester 3 0
Puerperium 5 18.5
Delivery mode
�
Normal vaginal delivery 15 58.0
Cesarean delivery 11 42.0
Table 1. Characteristics of patients with ovarian cancers during
pregnancy
No. of patients (%) Histologic type  
Table 2. Histopathologic characteristics of ovarian cancer (n=27)
Invasive epithelial malignancies, Six in unilateral ovarian malignancy with an intact capsule, One is clear cell type, FIGO stage IIIC.
*one patient has recurred after 19 months after initial surgical management.
USO, unilateral salpingo-oophorectomy.
Cystectomy Histopathology Operation USO
USO with 
omentectomy,
multiple biopsies
Complete staging 
operation
with hysterectomy
Borderline malignancy (n=15) 7 (46.6%) 6 (40%)  2 (13.4%) 0
Invasive epithelial malignancies (n=7) 1 (14.3%) 5* (71.4%) 0 1 (14.3%)
Germ cell tumor (n=5) 2 (40%) 2 (40%) 1 (20%) 0
Table 3. Surgical management by histologic type (n=27)
Borderline malignancies 
Mucinous 10  (30.0)
Serous 5 (18.5)
Invasive Epithelial malignancies
Mucinous 5 (18.5)
Serous 1 (3.7) 
Clear cell type 1 (3.7)
Germ cell tumors
Endodermal sinus tumor 1 (3.7)
Dysgerminoma 1 (3.7)
Immature teratoma 3 (11.1)232 Y.-S. Kwon, J.-E. Mok, K.-T. Lim, et al.
ent with EOC complicating ectopic pregnancy received post-
operative chemotherapy. Of five patients with germ cell tumor,
3 patients received it with the fetus in utero (range, 22.8-30.6
weeks of GA) and two patients at 2 weeks after cesarean deliv-
ery with 4 courses of bleomycin, etoposide and cisplatin (BEP).
Three patients with EOC received 6 courses of paclitaxel plus
carboplatin at 2 weeks after cesarean delivery. All 26 patients
with ovarian cancer complicating pregnancy were successful
in having a full term delivery. Of the 26 healthy full-term
infants, 15 were delivered by normal vaginal delivery and
eleven were by cesarean section. No congenital malformations
were detected in any of the 26 newborns. Neither dystocia
nor tumor metastasis to the placenta or fetus was recorded.
DISCUSSION
Most patients with ovarian cancer have no specific symp-
toms. This asymptomatic character of ovarian cancer makes
early diagnosis difficult. An ultrasound sonogram is a routine
method for evaluating fetal status in women with pregnan-
cy and it can also be used for early detection of an incidental
ovarian tumor. With the wide use of routine prenatal ultra-
sound, finding of an adnexal mass in pregnancy is increasing
(4). In contrast to past delivery modes, cesarean delivery is
now more frequent, and this can also contribute to the early
incidental diagnosis of ovarian tumor complicating pregnancy. 
The incidence of ovarian tumor detected during pregnan-
cy is 1/300 to 1/556 pregnancies (5-7). Of the ovarian tumors
detected during pregnancy, the incidence of ovarian malig-
nancy is 1/15,000 to 1/32,000 in the most reports (4, 8). In
our series, ovarian cancer during pregnancy occurred in 0.29/
1,000 deliveries (from 1996 to 2006, from 92,370 deliver-
ies at Cheil General Hospital and Women’s Healthcare Cen-
ter). This high incidence could be explained by recent wide
use of ultrasound examination as a routine antenatal evalua-
tion in our hospital.
Several studies have reported that the histologic types of
ovarian cancers during pregnancy are similar to those for non-
pregnant women in the corresponding reproductive-age group
(4, 9-11). In our series, borderline malignancy and invasive
epithelial ovarian cancer were more dominant than other types
of malignancies (Table 4). 
In white women, dysgerminoma is the most common ovar-
ian germ cell tumor coexisting with pregnancy, and consti-
tutes 25-35% of all reported ovarian cancers (9, 12, 13). How-
ever, the most common subtype of germ cell tumor in our
study was immature teratoma.
Surgical management of an adnexal mass, diagnosed dur-
ing pregnancy, creates a dilemma to gynecologists. It is dif-
ficult to discriminate ovarian malignancies from functional
cysts or benign ovarian tumors. If an adnexal mass, larger than
6 cm, has a complex structure, or ascites or persists for 16
gestational weeks, surgical management is critical for obtain-
ing a final histologic diagnosis and ruling out malignancy
(14). 
When any surgical intervention is needed for an adnexal
mass during pregnancy, the surgery should be performed dur-
ing the safest period of pregnancy. Elective surgery for tumors
with low suspicion of malignancy should be delayed until
the second trimester (16-18 weeks of gestation), when risk
for spontaneous abortion, hormonal dependence of the corpus
luteum of pregnancy is reduced, and when functional cysts are
resolved in the vast majority of cases (15). In the first trimester,
spontaneous abortion rate after surgery has been document-
ed to be 10%, while 76.3% patients progress to full-term
delivery (16). A mass, first noticed in the third trimester, is
best managed by awaiting fetal maturity as long as the clin-
ical suspicion of malignancy is low. Premature labor is more
likely to occur and pregnancy outcome is poor if surgical explo-
ration is attempted during the third trimester (17, 18). 
The principles of management in ovarian cancer compli-
cating pregnancy include surgery with adequate staging.
For advanced disease, the principles of adequate staging and
debulking surgery should be similar to those used for the treat-
ment of nonpregnant women. For most early-stage ovarian
cancers, the surgical principles should be unilateral oophorec-
tomy or adnexectomy with appropriate staging. Especially,
in borderline ovarian malignancies and germ cell tumors, it
is imperative to use conservative surgical strategies to main-
tain pregnancy. In our series, of 20 patients with borderline
malignancies (n=15) and germ cell tumors (n=5), 9 patients
*Number in parenthesis, reference number.
Author/year
Dgani et al./
1989 (9)*
Copeland and
Landon/1996 (10)
Zanotti et al./
2000 (4)
PUMCH/
2003 (31)
Behtash et al./
2008 (11)
This study
Histopathology
Epithelial  65% (15/23) 37.5% 33-40% 50% (11/22) 39.1% 81.5% (22/27)
Borderline 35%  (8/23) - 2/3 27.3% (6/22) 21.7% 55.5% (15/27)
Invasive 30% (7/23) - 1/3 22.7% (5/22) 17.4% 25.9% (7/27)
Germ cell  17% (4/23) 45% 30-33% 40.9% (9/22) 47.8% 18.5% (5/27)
Sex cord-stromal  13% (3/23) 10% 17-20% 9.1% (2/22) 13% 0% (0/27)
Others 5% (1/23) 7.5% 12-13% 0% (0/22) 0% 0% (0/27)
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received cystectomy, 8 patients received USO and 3 patients
received USO with omentectomy and multiple biopsy as the
initial surgical management. And all 5 patients with germ
cell tumor received BEP (cisplatin, bleomycin, and etoposide)
chemotherapy without any feto-maternal complications. Most
malignant ovarian germ cell tumors could be treated by con-
servative surgery without compromising survival since these
tumors are very sensitive to standard combinational chemother-
apy (19). And borderline malignancies differ from invasive
epithelial ovarian cancer in their indolent behavior and good
prognosis. All six cases in Gotlieb’s report (20) with imme-
diate conservative surgery preserving pregnancy had satis-
factory outcomes. Since there was no established benefit from
postoperative therapy for ovarian borderline malignancy, even
in late-stage diseases (21), conservative surgery is safe for these
tumors (20, 22). Conservative surgical management for most
malignant ovarian germ cell tumors and borderline malig-
nancies diagnosed during pregnancy should be considered
as the proper initial treatment.
Invasive epithelial cancer has the worst prognosis of all types
of ovarian cancers. The standard management of EOC is based
on the primary surgery, including hysterectomy and bilateral
salpingo-oophorectomy with peritoneal sampling (peritoneal
washing, omentectomy, multiple peritoneal biopsies and the
removal of peritoneal implants) with lymph-node biopsy.
Recently, with the help of several developed diagnostic tools,
and an increase in self-health monitoring among women,
early detection of ovarian cancer has increased and with the
widespread use of routine prenatal ultrasound, the finding
of an adnexal mass during pregnancy is an increasingly com-
mon occurrence. In contrast to past strategies for managing
EOC, most young patients with malignancies desire to be
managed focused on the quality of life after treatment, and to
maintain the pregnancy if possible. However, frequent relapse
of EOC makes conservative treatment strictly limited to pati-
ents with early stage EOC and low risks. In our study, 6 of
7 patients with EOC received comprehensive rather than com-
plete staging operations (1 cystectomy and 5 USO). One of
these six (16.6%) patients recurred. Our study demonstrates
that in EOC complicating pregnancy, conservative manage-
ment with adequate staging procedures should be considered
for oncologic safety.
Generally, chemotherapy is compatible with the second
or third trimester, when the risk of congenital malformation
for fetuses exposed to chemotherapy is no greater than in the
general population (23, 24). In our study, three patients with
germ cell tumors received BEP chemotherapy during preg-
nancy, all of which had healthy babies without congenital
malformations. The literature contains numerous reports of
BEP regimen and adjuvant cisplatin and cyclophosphamide
used in pregnancy with no untoward effects (8, 25-28). There
were a few case reports describing the combined use of pacli-
taxel and carboplatin in human pregnancy, and there seems
to be no significant fetal toxicity when these are administered
during the second or third trimester (29, 30). Recently, no
studies have evaluated the long-term consequences for chil-
dren exposed to intrauterine chemotherapy. To establish stan-
dard guidelines for treatment and improve the quality of life
in patients with pregnancy complicating ovarian cancer with
an oncologic safety, the further studies regarding the proper
management of these patients should be advanced.
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